Companies
From start-ups to market leaders, access critical company intelligence on a global scale
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
Brexit Implications Report, Brexit in Healthcare Report
There is much uncertainty as to what the UK healthcare industry will look like after Brexit.
More than half of participants we interviewed agreed that the UK would take at least three years for its healthcare industry to stabilize in the event of a “No Deal” Brexit. Currently the pharmaceutical industry is a leading sector of wealth, with a growth value added to the UK economy of £13.8M ($21.7M*) in 2016. GlaxoSmithKline and AstraZeneca are UK-headquartered and generated combined global sales of over $61B in 2018 alone. The UK also has sizeable operations from leading multinational companies such as Pfizer, Roche, Novartis, and Johnson & Johnson (J&J).
It has been over three years since the UK voted to leave the EU. As Brexit deadlines loom, negotiations are still ongoing to determine the UK’s relationship with the EU after Brexit.
Our Brexit in Healthcare report series provides in-house analyst expertise on the results of a survey of GlobalData Pharma clients and prospects. Participants answered questions about how they expect Brexit to affect healthcare, both from within and outside of the UK.